BidaskClub upgraded shares of Cardiovascular Systems (NASDAQ:CSII) from a hold rating to a buy rating in a report published on Friday.

Other equities research analysts also recently issued reports about the company. Lake Street Capital reaffirmed a buy rating and issued a $50.00 price target on shares of Cardiovascular Systems in a research report on Wednesday, August 1st. ValuEngine raised Cardiovascular Systems from a hold rating to a buy rating in a research report on Friday, July 6th. Needham & Company LLC reissued a hold rating on shares of Cardiovascular Systems in a research report on Thursday, May 3rd. Zacks Investment Research downgraded Cardiovascular Systems from a buy rating to a hold rating in a research report on Friday, August 3rd. Finally, Bank of America raised Cardiovascular Systems from an underperform rating to a buy rating in a research report on Wednesday, June 27th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $32.75.

Shares of NASDAQ:CSII opened at $37.24 on Friday. The stock has a market capitalization of $1.25 billion, a PE ratio of 747.60 and a beta of 2.41. Cardiovascular Systems has a 52-week low of $20.58 and a 52-week high of $39.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.99 and a current ratio of 4.46.

Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Monday, July 30th. The medical device company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.05. The company had revenue of $59.15 million for the quarter, compared to the consensus estimate of $58.43 million. Cardiovascular Systems had a return on equity of 1.39% and a net margin of 0.79%. sell-side analysts predict that Cardiovascular Systems will post 0.02 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in Cardiovascular Systems by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 298,694 shares of the medical device company’s stock worth $7,075,000 after buying an additional 12,584 shares in the last quarter. Swiss National Bank grew its position in Cardiovascular Systems by 5.5% during the first quarter. Swiss National Bank now owns 57,800 shares of the medical device company’s stock worth $1,268,000 after buying an additional 3,000 shares in the last quarter. Thomson Horstmann & Bryant Inc. grew its position in Cardiovascular Systems by 16.0% during the first quarter. Thomson Horstmann & Bryant Inc. now owns 169,514 shares of the medical device company’s stock worth $3,717,000 after buying an additional 23,325 shares in the last quarter. Cortina Asset Management LLC grew its position in Cardiovascular Systems by 8.6% during the first quarter. Cortina Asset Management LLC now owns 841,013 shares of the medical device company’s stock worth $18,443,000 after buying an additional 66,768 shares in the last quarter. Finally, Champlain Investment Partners LLC grew its position in Cardiovascular Systems by 15.0% during the first quarter. Champlain Investment Partners LLC now owns 2,590,330 shares of the medical device company’s stock worth $56,806,000 after buying an additional 336,975 shares in the last quarter. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc, a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Recommended Story: Average Daily Trade Volume – ADTV

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.